Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction

被引：5

作者：

Davidson, Michael H. ^{[1
,2
]}

机构：

[1] Univ Chicago, Pritzker Sch Med, Cardiol Sect, Dept Med, Chicago, IL 60637 USA

[2] Radiant Res, Chicago, IL 60654 USA

来源：

CARDIOLOGY CLINICS | 2011年 / 29卷 / 01期

关键词：

High-density lipoprotein cholesterol; Coronary heart disease; High-density lipoprotein particles; Reverse cholesterol transport; Risk reduction; THERAPEUTIC TARGET; METABOLIC SYNDROME; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; CHOLESTEROL LEVELS; PROSTAGLANDIN D-2; HDL CHOLESTEROL; ARTERY-DISEASE; NICOTINIC-ACID; DOUBLE-BLIND;

D O I：

10.1016/j.ccl.2010.11.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A low level of high-density lipoprotein (HDL) is an acknowledged risk factor for coronary heart disease (CHD). HDL cholesterol (HDL-C) exerts its primary cardioprotective effect through a reverse cholesterol transport process, and suppression of this process has been the focus of the development of novel therapeutic agents for increasing HDL-C levels. Several strategies can be used to increase HDL-C levels to target cardiovascular risk reduction. This article presents a review of the biologic actions of HDL that can serve as a potential basis for antiatherosclerotic activity and discusses strategies for targeting HDL for CHD risk reduction.

引用

页码：105 / +

页数：19

共 53 条

[1]

[Anonymous], HEART DIS STROK STAT

[2] Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial [J].

Barter, Philip .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (10A) :10E-15E

[3] Antiinflammatory properties of HDL [J].

Barter, PJ ;

Nicholls, S ;

Rye, KA ;

Anantharamaiah, GM ;

Navab, M ;

Fogelman, AM .

CIRCULATION RESEARCH, 2004, 95 (08) :764-772

[4] CORONARY DRUG PROJECT - EXPERIENCE WITH NIACIN [J].

BERGE, KG ;

CANNER, PL .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 :S49-S51

[5] Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials [J].

Birjmohun, RS ;

Hutten, BA ;

Kastelein, JJP ;

Stroes, ESG .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :185-197

[6] Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women [J].

Blake, GJ ;

Otvos, JD ;

Rifai, N ;

Ridker, PM .

CIRCULATION, 2002, 106 (15) :1930-1937

[7] Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib [J].

Cannon, Christopher P. ;

Dansky, Hayes M. ;

Davidson, Michael ;

Gotto, Antonio M., Jr. ;

Brinton, Eliot A. ;

Gould, A. Lawrence ;

Stepanavage, Michael ;

Liu, Sherry Xueyu ;

Shah, Sukrut ;

Rubino, Joseph ;

Gibbons, Patrice ;

Hermanowski-Vosatka, Anne ;

Binkowitz, Bruce ;

Mitchel, Yale ;

Barter, Philip .

AMERICAN HEART JOURNAL, 2009, 158 (04) :513-+

[8] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].

CASTELLI, WP ;

GARRISON, RJ ;

WILSON, PWF ;

ABBOTT, RD ;

KALOUSDIAN, S ;

KANNEL, WB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838

[9]

CASTELLI WP, 1988, CAN J CARDIOL, V4, pA5

[10] Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans [J].

Cheng, K ;

Wu, TJ ;

Wu, KK ;

Sturino, C ;

Metters, K ;

Gottesdiener, K ;

Wright, SD ;

Wang, ZY ;

O'Neill, G ;

Lai, E ;

Waters, MG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (17) :6682-6687

← 1 2 3 4 5 6 →